Current status of autologous stem cell transplantation for multiple myeloma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current status of autologous stem cell transplantation for multiple myeloma
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 9, Issue 4, Pages -
Publisher
Springer Nature
Online
2019-04-08
DOI
10.1038/s41408-019-0205-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
- (2018) Parameswaran Hari et al. BONE MARROW TRANSPLANTATION
- Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients-DAUTOS Study of the Polish Myeloma Study Group
- (2018) Anna Waszczuk-Gajda et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased efficacy of stem cell chemo-mobilization with intermediate-dose cytarabine plus G-CSF compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial,
- (2018) Tomasz Czerw et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma
- (2018) Kevin C. Miller et al. BONE MARROW TRANSPLANTATION
- Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients
- (2018) Sarah Farag et al. HEMATOLOGICAL ONCOLOGY
- Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma
- (2017) Suzanne C. Gettys et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma
- (2017) Guorong Wang et al. MEDICINE
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
- (2016) Philippe Moreau et al. BLOOD
- A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
- (2016) M Martino et al. BONE MARROW TRANSPLANTATION
- Singleversustandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
- (2016) Elias K. Mai et al. BRITISH JOURNAL OF HAEMATOLOGY
- Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
- (2016) Christian Straka et al. HAEMATOLOGICA
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
- (2016) Christian Straka et al. HAEMATOLOGICA
- The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
- (2016) Gordon Cook et al. Lancet Haematology
- Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma
- (2015) Moritz Binder et al. AMERICAN JOURNAL OF HEMATOLOGY
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
- (2015) Sergio Giralt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Frontline therapy of multiple myeloma
- (2015) P. Moreau et al. BLOOD
- A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma
- (2015) R Silvennoinen et al. BONE MARROW TRANSPLANTATION
- A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
- (2015) W I Bensinger et al. BONE MARROW TRANSPLANTATION
- Multiple Myeloma, Version 2.2016
- (2015) Kenneth C. Anderson et al. Journal of the National Comprehensive Cancer Network
- Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
- (2015) Francesca Gay et al. LANCET ONCOLOGY
- How we manage autologous stem cell transplantation for patients with multiple myeloma
- (2014) M. A. Gertz et al. BLOOD
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
- (2014) P. Sonneveld et al. BLOOD
- Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers
- (2014) M. Mohty et al. HAEMATOLOGICA
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
- (2014) P. G. Richardson et al. Hematology-American Society of Hematology Education Program
- Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
- (2013) F. Gay et al. BLOOD
- A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
- (2013) A. K. Stewart et al. BLOOD
- Second autologous transplant as salvage therapy in multiple myeloma
- (2013) Djordje Atanackovic et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
- (2013) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies
- (2012) Dawn Sheppard et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
- (2012) Margarita Blanes et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial
- (2012) N. Russell et al. HAEMATOLOGICA
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
- (2012) Heinz Ludwig et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization
- (2012) S Li et al. LEUKEMIA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
- (2011) Florent Malard et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
- (2011) P. Moreau et al. BLOOD
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
- (2011) M. Cavo et al. BLOOD
- In and out of the niche: perspectives in mobilization of hematopoietic stem cells
- (2011) Mohamad Mohty et al. EXPERIMENTAL HEMATOLOGY
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
- (2011) G. J. Morgan et al. HAEMATOLOGICA
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
- (2011) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies
- (2011) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation
- (2011) M Mohty et al. LEUKEMIA
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
- (2010) P. Moreau et al. BLOOD
- Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
- (2010) J. J. Lahuerta et al. HAEMATOLOGICA
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
- (2009) H. M. Lokhorst et al. BLOOD
- Improving stem cell mobilization strategies: future directions
- (2009) W Bensinger et al. BONE MARROW TRANSPLANTATION
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
- (2009) Andrew Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
- (2009) Jean-Luc Harousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Making progress in treating multiple myeloma with total therapies: issue of complete remission and more
- (2008) B Barlogie et al. LEUKEMIA
- Improved Granulocyte Colony-Stimulating Factor Mobilization of Hemopoietic Progenitors Using Cytokine Combinations in Primates
- (2008) Stephen R. Larsen et al. STEM CELLS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now